KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Inventory (2020 - 2025)

Moderna (MRNA) has disclosed Change in Inventory for 6 consecutive years, with -$179.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 38.49% to -$179.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.0 million, a 140.96% increase, with the full-year FY2025 number at $34.0 million, up 140.96% from a year prior.
  • Change in Inventory was -$179.0 million for Q4 2025 at Moderna, down from $91.0 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $501.0 million in Q1 2022 to a low of -$1.1 billion in Q4 2022.
  • A 5-year average of $5.3 million and a median of $51.0 million in 2024 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: soared 912.77% in 2021, then plummeted 336.97% in 2022.
  • Moderna's Change in Inventory stood at $476.0 million in 2021, then tumbled by 336.97% to -$1.1 billion in 2022, then surged by 74.73% to -$285.0 million in 2023, then fell by 2.11% to -$291.0 million in 2024, then surged by 38.49% to -$179.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Change in Inventory are -$179.0 million (Q4 2025), $91.0 million (Q3 2025), and $114.0 million (Q2 2025).